Marc Vincent Barcelona, MD, FPCR, DPBR-RO (@MarcBarcieMD) header
Marc Vincent Barcelona, MD, FPCR, DPBR-RO (@MarcBarcieMD) profile picture

#RadOnc Fellow @RadMedPM, hubby of #Peds #HemOnc, clinical cancer research, interests in #hncsm #pcsm #bcsm #kcsm #oligomets #MRgRT #IGBT #SBRT

National Capital Region
Joined April 2022
Photo by Marc Vincent Barcelona, MD, FPCR, DPBR-RO (@MarcBarcieMD)Photo by Marc Vincent Barcelona, MD, FPCR, DPBR-RO (@MarcBarcieMD)Photo by Marc Vincent Barcelona, MD, FPCR, DPBR-RO (@MarcBarcieMD)
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
Editorial Randomized trial resected brain met Brachytherapy vs Post-Op SRS Incredible Surg Bed Control with Brachy (↑↑OS as well) Look forward to results NRG BN012 NRG BN012 pre vs. post-op SRS hopefully ↓↓ LMD ascopubs.org/doi/10.1200/JCO…
2
9
27
1,340
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
Guidelines for baseline 🧠 MRI across cancers 🫁NSCLC - Stage II onwards, >3cm 🫁SCLC - All, #MAVERICK surveillance avoids PCI #Breast - Only if symptomatic, ESMO - all IV TNBC & HER2+ #Melanoma - If N+ or IV What's your practice in other sites? #lcsm #bcsm #skin #cancer #lung
10
26
1,587
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
Not often do we publish 2 back to back guidelines on #NasopharyngealCarcinoma in @JCO_ASCO Was a pleasure leading this monumental effort with @BrigetteMa2 @ASCO CSCO 💪🏻💪🏻💪🏻 Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
6
22
1
52
2,829
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
To the person who hit him: you’ll never know how his story ended. But we do, and it’s a happy one. 🐾
48
597
6
7,117
30,694
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
The ending little Bruno deserved. Priceless to see how happy he is ❤️
214
1,762
23
16,163
135,610
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
For the first six months of his life, Timothee knew nothing but the four walls of a tiny cage 💔 When we first rescued him, his back legs hadn't developed properly, and even walking was a struggle. But with time, patience and lots of love, Timothee has come such a long way. From barely being able to walk to running freely, he's made the most incredible progress. Now he's learning something else entirely, what it means to live inside a home. Sofas, furniture and all the little comforts most dogs have always known are completely new to him. There have been a few little bumps along the way, but he's getting there❤️ The only thing missing now is a family to call his own.
73
967
13
9,039
51,752
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
6 weeks ago this is how we found Bruno on the side of the street. He had been hit and dragged under a car. Nobody was stopping. You won’t believe the ending today for lovely Bruno… (1/6)
147
1,967
41
18,364
309,871
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
reminding #radonc dose >100% of Rx dose inside PTV not a "hotspot" it is a heterogeneity Hot spots *always* outside PTV little pedantry for @Advances_ASTRO, @HoppeBrad et al ;) should be "Heterogeneity <120%" etc aekwl.de/fileadmin/qualitaet… teapawt.org/toddscarbrough/status/…
🫁🌶️ SPICE-ing up lung SBRT Intentional tumor 🔥hotspot (PTV Dmax ≥120%) vs <120% in VMAT SBRT for early-stage NSCLC 3-year local recurrence rates: 🔥0% with ≥120% hotspot 🧊8-9% with <120% hotspot 📚 Not a novel concept. Prior work has suggested that higher intratumoral dose improves local control! ✅ What this study contributes is additional clinical evidence, plus a practical planning strategy (SPICE: Stereotactic Planning with Intentional Central Escalation). ⚠️ No PFS or OS advantage seen. 🎯Take-home: Another data point supporting intentional hotspot escalation in lung SBRT, rather than proof of a brand-new concept @ASTRO_org advancesradonc.org/article/S…
4
27
1,712
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
👋Congratulations to @imrtlee @EChrisDee @xrtGenomics @seanmmcbride @DrPaulRomesser and the entire team at @MSKCancerCenter @MSK_RadOnc. Many, many years in the making! 🚨Quad Shot (14.8 Gy BID*4fx; q 3 weeks) is an excellent re-RT option for centers yet to adopt it.
🧵 Excited to share our multicenter, prospective phase 2 trial of proton re-irradiation for people with recurrent head & neck cancer, now in @JournalCancer Grateful to Dr @IMRTLee @xrtGenomics @DrPaulRomesser and team for the opportunity to write 🙏 🔗 acsjournals.onlinelibrary.wi…
3
18
1,517
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
Important limitations: This was a nonrandomized phase 2 trial, not a proton-versus-photon comparison. The cohorts differed in disease burden, prior treatments, and clinical goals. We cannot conclude that protons are superior or that one fractionation approach is better.
1
1
1
4
1,510
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
But we must be transparent about toxicity. Late grade 3 toxicity occurred in 20%, grade 4 in 11%, and grade 5 in 4%. Three patients experienced fatal bleeding events, all after biopsies. These risks must be central to counseling and shared decision-making.
2
4
1
10
1,244
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
Optimizing Therapy for Locally Advanced #ProstateCancer. Presented by @BarbaraJereczek. #ESMO26 written coverage by @zklaassen_md > bit.ly/4z7fiav #RadOnc #GUOnc @myESMO
15
1
44
3,772
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
Excited to share our new study in Eur J Cancer @EORTC, led by Drs @Haoshen_Cheng, @Alex_Terry1, @imrtlee, @TabarViviane, and team! Does proton therapy affect the risk of RT-induced brain necrosis compared with IMRT in patients w nasopharyngeal cancer? 🔗 pubmed.ncbi.nlm.nih.gov/4294…
2
6
1
23
1,352
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
CAN-2409 + valacyclovir added to RT improved DFS in intermediate/high-risk prostate cancer (HR 0.70; phase 3, n=745). Grade ≥3 AEs were 8% vs 7%. Long-term follow-up is ongoing; the therapy remains investigational. pubmed.ncbi.nlm.nih.gov/4222…
3
7
467
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
PE-PE is a fantastic study, giving us randomized data on adding pembrolizumab to MDT in oligometastatic RCC! Phase II, open-label, multicenter trial: 85 pts with prior nephrectomy and ≤3 mets within 5y of nephrectomy or previous metastasectomy, all amenable to surgery or SABR. Randomized 2:1 favoring pembro: MDT alone (n=29) vs pembro + MDT (n=56). Pembro 400 mg q6w x9c (1y). First dose BEFORE MDT; registry specifies MDT on C1d21-42. At MFU 17.5 mo, median RFS was 11→ 25.4 mo (HR 0.47, 95CI 0.24-0.92, p=0.024), MDT alone→ pembro + MDT. 35 RFS events, 16→ 19. SABR 72→ 73%; surgery 28→ 23%. SABR dose/fx and per-site data weren't reported. I'd like to see those details along with local vs distant relapse. Any AE 21→ 80%; G3 AEs 3→ 7%. The 21% control rate is with no study systemic therapy. Pembro-related AEs occurred in 59%, including G3 in 2 pts; no G4/5 pembro-related events were reported. Four pts stopped pembro for AEs. Both groups received MDT, so the randomized question is what pembro adds. This doesn't establish the benefit of MDT itself or RT-ICI synergy. With 1 death/arm and no QoL results reported, an OS/QoL benefit remains unestablished. I'd also like the prior systemic therapy history and the timing/burden at first metastatic presentation. The eligibility window alone doesn't tell us whether these pts were oligometastatic from the outset. Congratulations to the investigators on this important work! cslide.ctimeetingtech.com/es… #radonc #ESMO26 #RCC
Proud to report at #ESMO2026 the results of PE-PE trial. Oligometastatic #RCC pts have a significant benefit when pembro was added to MDT irrespectively of the type of MDT used and up to 5y from previous surgery. Thanks to the 🇮🇹 team and special thanks to @DrChoueiri! @OncoAlert @urotoday @myESMO @KidneyCancer @Sebastiano_Buti @ciccarese_c @fmassari79 @mimma_rizzo @elena_verzoni @MatteoSantoniMD
1
9
1
23
2,710
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
Revisit this phase 3 study from @ESTRO_RT @EORTC_BCG: Nodal irradiation for breast cancer decreases breast-cancer related mortality but increases non-breast cancer related mortality after 22.2 years in @EORTC trial 22922/10925. 🔗: acsjournals.onlinelibrary.wi… @OncoAlert #BCSM
8
10
1,004
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
📢 Our practical guide to EBRT for HCC is out in PRO Less of a lit review, more of a how-to for #radonc: pt selection, techniques, treatment delivery, special scenarios Many thanks to all coauthors! @ldawsonmd @AndrewMMoon @hmaxi_MD @MichaelYanMD 🔗 tinyurl.com/PROHCC
3
50
132
6,541
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
Long-term OS benefit w/ abiraterone in PEACE-1 (2215O). Note this is triplet vs ADT + docetaxel, not vs ADT + ARPI. 📌 Randomized phase 3, 2x2 factorial, 1,173 men w/ de novo mCSPC. High / low volume 57 / 43%. 📌 R 1:1:1:1 to SoC (ADT ± docetaxel), SoC + prostate RT 74/37, SoC + abi/prednisone, or SoC + abi/prednisone + RT. 📌 Median follow-up 7.7y. Among control-arm pts whose disease progressed, 86% received an ARPI. 📌 Adding abi to SoC: OS HR 0.75 (95% CI 0.65-0.87; p=0.0001). Pooled mOS 4.6→ 6.1y (ESMO press release). 📌 ADT + docetaxel ± abi (n=710): mOS 4.4→ 6.2y; HR 0.68 (95% CI 0.56-0.82). 8y OS 27.1→ 40.3%. This was not triplet vs ADT + ARPI doublet. 📌 High-volume mOS 3.5→ 4.6y, HR 0.68 (95% CI 0.54-0.85); low-volume 6.2→ 7.8y, HR 0.74 (95% CI 0.52-1.05). No detected volume interaction (p=0.56); low-volume OS not independently significant. 📌 G3-4 AEs, doublet→ triplet without RT (press release): HTN 14→ 21%; hypokalemia 1→ 4%. No new long-term safety signal reported. Side note on RT: in the 2024 Lancet RT analysis, prostate RT did not improve OS, but improved CRPC-free survival regardless of burden (HR 0.79, 95% CI 0.69-0.90), low-volume rPFS w/ abi (4.4→ 7.5y; aHR 0.65, 99.9% CI 0.36-1.19; RT effect p=0.019; no rPFS gain w/o abi; RT x abi interaction p=0.026), and reduced serious GU events (22.3→ 12.2%). ESMO 2026 reports RT only through four-arm mOS: SoC / SoC + RT / SoC + abi / SoC + abi + RT 4.6 / 4.6 / 5.7 / 6.4y. No new CRPC-free or GU-event RT data. cslide.ctimeetingtech.com/es… #ESMO26 #PCSM #radonc
6
20
1,141
Marc Vincent Barcelona, MD, FPCR, DPBR-RO retweeted
Impressive IST (as always!) from @DrIacovelli. We often talk about application of pembro as “adjuvant” after treating oligometastatic disease. Now we have data to back it up. Maybe (as med oncs) we get pembro going as we work out MDT approach for oligomets? Discussant suggests a P3 - I’m not sure it will get done. With reasonable data for pembro in M1 NED, I say go for it. #ESMO26 @OncoAlert
1
17
1
44
1,814